Antiproliferative activity of dmoPTA–Ru(II) complexes against human solid tumor cells

Complexing Properties of Synthesized 1,3,5-Triaza-7-Phosphaadamantane Derivatives Towards Some Lanthanides and Transition Metal Cations With Significant Antimicrobial and Antioxidant Activities

The synthesis of new water-soluble N-alkylated derivatives of 1,3,5-triaza-7-phosphaadamantane is presented. Ru(PPh3)2Cl2 has been used to react with 1-(4-nitrobenzyl)-3,5-triaza-1-azonia-7-phosphaadamantane bromide (PTAR). By using elemental analysis, NMR, and IR spectroscopy, the obtained compounds were identified. The UV-visible absorption spectroscopy has been used to monitor the complexation of various transition metal cations. Studies on conductivity have been utilized to validate the complexes' stoichiometries. Using the disc diffusion method, five bacteria strains were used for the study of the antimicrobial activity of compounds 1-3. All tested pathogens, including M luteus LB 141107, were found to have strong biologic activity against the compounds tested in this study. Additionally, DPPH (2,2-diphenyl-1-picrylhydrazyl) has been tested for its ability to scavenge hydrogen peroxide and free radicals. According to our results, these compounds exhibit excellent radical scavenging properties.

Insights into the κ-P,N Coordination of 1,3,5-Triaza-7-phosphaadamantane and Derivatives: κ-P,N-Heterometallic Complexes and a 15N Nuclear Magnetic Resonance Survey

Complexes {[(PTA)₂CpRu-μ-CN-1κC:2κ²N-RuCp(PTA)₂-ZnCl₃]}·2DMSO (13) {[ZnCl₂(H₂O)]-(PTA-1κP:2κ²N)(PTA)CpRu-μ-CN-1κC:2κ²N-RuCp(PTA)(PTA-1κP:2κ²N)-[ZnCl₂(H₂O)]}Cl (14), [RuCp(HdmoPTA)(PPh₃)(PTA)](CF₃SO₃)₂ (20), [RuCp(HdmoPTA)(HPTA)(PPh₃)](CF₃SO₃)₃ (21), and [RuCp(dmoPTA)(PPh₃)(PTA)](CF₃SO₃) (22) were obtained and characterized, and their crystal structure together with that of the previously published complex 18 is reported. The behavior of the 1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane (PTA) and 3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane (dmoPTA) ligands against protonation and κN-coordination is discussed, on the basis of ¹⁵N nuclear magnetic resonance data collected on 22 different compounds, including PTA (1), HdmoPTA (7H), and some common derivatives as free ligands (2–6 and 8), along with mono- and polymetallic complexes containing PTA and/or HdmoPTA (9–22). ¹⁵N detection via ¹H–¹⁵N heteronuclear multiple bond correlation allowed the construction of a small library of ¹⁵N chemical shifts that shed light on important features regarding κN-coordination in PTA and its derivatives.

To shed light on the behavior of the triazaphosphines 1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane (PTA) and 3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane (dmoPTA) upon κN coordination and N protonation, the ¹⁵N chemical shifts of 22 compounds, including PTA and a representative variety of its derivatives, piano-stool complexes, were collected by ¹H−¹⁵N heteronuclear multiple bond correlation nuclear magnetic resonance. New heterometallic complexes containing PTA were also synthesized and fully characterized.

Zinc Complexes with Nitrogen Donor Ligands as Anticancer Agents

The search for anticancer metal-based drugs alternative to platinum derivatives could not exclude zinc derivatives due to the importance of this metal for the correct functioning of the human body. Zinc, the second most abundant trace element in the human body, is one of the most important micro-elements essential for human physiology. Its ubiquity in thousands of proteins and enzymes is related to its chemical features, in particular its lack of redox activity and its ability to support different coordination geometries and to promote fast ligands exchange. Analogously to other trace elements, the impairment of its homeostasis can lead to various diseases and in some cases can be also related to cancer development. However, in addition to its physiological role, zinc can have beneficial therapeutic and preventive effects on infectious diseases and, compared to other metal-based drugs, Zn(II) complexes generally exert lower toxicity and offer few side effects. Zinc derivatives have been proposed as antitumor agents and, among the great number of zinc coordination complexes which have been described so far, this review focuses on the design, synthesis and biological studies of zinc complexes comprising N-donor ligands and that have been reported within the last five years.

Water and catalytic isomerization of linear allylic alcohols by [RuCp(H2O-κO)(PTA)2]+(PTA = 1,3,5-triaza-7-phosphaadamantane)

The water soluble complex [RuCp(H₂O-κO)(PTA)₂]⁺showed to be an excellent catalyst for the isomerization of allylic alcohols from 3-buten-2-ol to 1-octen-3-ol in water, which was mandatory for obtaining the best conversion.

Enhancement of the antiproliferative activity of [RuCp(PPh3)2(dmoPTA-1κP)]+via its coordination to one {CoCl2} unit: synthesis, crystal structure and properties of [RuCp(PPh3)2-μ-dmoPTA-1κP:2κ2N,N′-CoCl2](OTf)·0.25H2O

Antiproliferative activity up to 354-fold for WiDr-colon cells than cisplatin.

Binuclear ruthenium complexes inhibit the fibril formation of human islet amyloid polypeptide

Binuclear ruthenium complexes reverse the aggregation of human islet amyloid polypeptide.

Roles of DMSO-type ruthenium complexes in disaggregation of prion neuropeptide PrP106–126

DMSO-type ruthenium complexes with aromatic ligands disaggregate the mature PrP106–126 fibrilsviametal coordination and hydrophobic interaction.

Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation

Prion diseases are a group of infectious and fatal neurodegenerative disorders caused by the conformational conversion of a cellular prion protein (PrP) into its abnormal isoform PrP(Sc). PrP106-126 resembles PrP(Sc) in terms of physicochemical and biological characteristics and is used as a common model for the treatment of prion diseases. Inhibitory effects on fibril formation and neurotoxicity of the prion neuropeptide PrP106-126 have been investigated using metal complexes as potential inhibitors. Nevertheless, the binding mechanism between metal complexes and the peptide remains unclear. The present study is focused on the interaction of PrP106-126 with NAMI-A and NAMI-A-like ruthenium complexes, including KP418, KP1019, and KP1019-2. Results demonstrated that these ruthenium complexes could bind to PrP106-126 in a distinctive binding mode through electrostatic and hydrophobic interactions. NAMI-A-like ruthenium complexes can also effectively inhibit the aggregation and fibril formation of PrP106-126. The complex KP1019 demonstrated the optimal inhibitory ability upon peptide aggregation, and cytotoxicity because of its large aromatic ligand contribution. The studied complexes could also regulate the copper redox chemistry of PrP106-126 and effectually inhibit the formation of reactive oxygen species. Given these findings, ruthenium complexes with relatively low cellular toxicity may be used to develop potential pharmaceutical products against prion diseases.

Synthesis and antiproliferative activity of the heterobimetallic complexes [RuClCp(PPh₃)-μ-dmoPTA-1κP:2κ²N,N'-MCl₂] (M = Co, Ni, Zn; dmoPTA = 3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)

The synthesis and characterization of three novel heterobimetallic derivatives of general formula [RuClCp(PPh₃)-μ-dmoPTA-1κP:2κ²N,N'-MCl₂] (M = Co (1), Ni (2) and Zn (3), dmoPTA = 3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane) are described. The sizes of their diffusing units are in agreement with the solid-state structures of 2 and 3, supporting a similar solid-state structure for complex 1. The diamagnetic ruthenium-zinc derivative 3 was fully characterized in solution at 193 K by NMR. Electrochemical properties of the complexes were investigated by cyclic voltammetry, supporting the influence of the {MCl₂} moiety on the electronic properties of the Ru-unit. For the three complexes the GI₅₀ values were in the range 0.8-6.5 μM and comparable to those of the standard anticancer drug cis-platin in the same cell lines.